Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 21;6(4):2137-54.
doi: 10.3390/cancers6042137.

Desmoplasia and chemoresistance in pancreatic cancer

Marvin Schober  1 , Ralf Jesenofsky  2 , Ralf Faissner  3 , Cornelius Weidenauer  4 , Wolfgang Hagmann  5 , Patrick Michl  6 , Rainer L Heuchel  7 , Stephan L Haas  8 , J-Matthias Löhr  9
Affiliations
Review

Desmoplasia and chemoresistance in pancreatic cancer

Marvin Schober et al. Cancers (Basel). .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) occurs mainly in people older than 50 years of age. Although great strides have been taken in treating PDAC over the past decades its incidence nearly equals its mortality rate and it was quoted as the 4th leading cause of cancer deaths in the U.S. in 2012. This review aims to focus on research models and scientific developments that help to explain the extraordinary resistance of PDAC towards current therapeutic regimens. Furthermore, it highlights the main features of drug resistance including mechanisms promoted by cancer cells or cancer stem cells (CSCs), as well as stromal cells, and the acellular components surrounding the tumor cells-known as peritumoral desmoplasia-that affects intra-tumoral drug delivery. Finally, therapeutic concepts and avenues for future research are suggested, based on the topics discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Octagon of environmental mediated drug resistance (EMDR) in pancreatic cancer. Soluble factor mediated drug resistance (SFM-DR), a form of EMDR (yellow), is shown in blue.
See this image and copyright information in PMC

References

    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012;62:10–29. - PubMed
    1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014;74:2913–2921. - PubMed
    1. Kleeff J., Michalski C., Friess H., Buchler M.W. Pancreatic cancer: From bench to 5-year survival. Pancreas. 2006;33:111–118. doi: 10.1097/01.mpa.0000229010.62538.f2. - DOI - PubMed
    1. Löhr M. Is it possible to survive pancreatic cancer? Nat. Clin. Pract. Gastroenterol. Hepatol. 2006;3:236–237. doi: 10.1038/ncpgasthep0469. - DOI - PubMed
    1. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010;362:1605–1617. doi: 10.1056/NEJMra0901557. - DOI - PubMed

LinkOut - more resources